PL2922530T3 - Formulacje octanu kaspofunginy - Google Patents

Formulacje octanu kaspofunginy

Info

Publication number
PL2922530T3
PL2922530T3 PL12810519T PL12810519T PL2922530T3 PL 2922530 T3 PL2922530 T3 PL 2922530T3 PL 12810519 T PL12810519 T PL 12810519T PL 12810519 T PL12810519 T PL 12810519T PL 2922530 T3 PL2922530 T3 PL 2922530T3
Authority
PL
Poland
Prior art keywords
caspofungin acetate
acetate formulations
formulations
caspofungin
acetate
Prior art date
Application number
PL12810519T
Other languages
English (en)
Inventor
Zhi-Qiang Jiang
Arunya Usayapant
David Bowman
Keith Kwok
Joel Peterson
Original Assignee
Fresenius Kabi Usa, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Usa, Llc filed Critical Fresenius Kabi Usa, Llc
Publication of PL2922530T3 publication Critical patent/PL2922530T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL12810519T 2012-11-20 2012-12-21 Formulacje octanu kaspofunginy PL2922530T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261728406P 2012-11-20 2012-11-20

Publications (1)

Publication Number Publication Date
PL2922530T3 true PL2922530T3 (pl) 2017-04-28

Family

ID=47505366

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12810519T PL2922530T3 (pl) 2012-11-20 2012-12-21 Formulacje octanu kaspofunginy

Country Status (14)

Country Link
US (4) US9636407B2 (pl)
EP (1) EP2922530B1 (pl)
CA (1) CA2888625A1 (pl)
CY (1) CY1120016T1 (pl)
DK (1) DK2922530T3 (pl)
ES (1) ES2607646T3 (pl)
HR (1) HRP20161703T1 (pl)
HU (1) HUE032392T2 (pl)
LT (1) LT2922530T (pl)
PL (1) PL2922530T3 (pl)
PT (1) PT2922530T (pl)
SI (1) SI2922530T1 (pl)
SM (1) SMT201600452B (pl)
WO (1) WO2014081443A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636407B2 (en) * 2012-11-20 2017-05-02 Fresenius Kabi Usa, Llc Caspofungin acetate formulations
WO2017185030A1 (en) * 2016-04-22 2017-10-26 Fresenius Kabi Usa, Llc Caspofungin formulation with low impurities
WO2019148282A1 (en) * 2018-02-01 2019-08-08 The Royal Institution For The Advancement Of Learning/Mcgill University Formulations for improving the delivery of hydrophobic agents
WO2019157453A1 (en) 2018-02-12 2019-08-15 Trilogy Therapeutics, Inc. Caspofungin compositions for inhalation
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
CN109758426B (zh) * 2019-01-24 2021-04-27 四川制药制剂有限公司 一种注射用醋酸卡泊芬净药物组合物及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378804A (en) * 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
ES2181790T3 (es) 1994-09-16 2003-03-01 Merck & Co Inc Compuestos azaciclohexapeptidicos.
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5552521A (en) 1995-02-10 1996-09-03 Merck & Co., Inc. Process for preparing certain aza cyclohexapeptides
US5952300A (en) * 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
USRE38984E1 (en) 1996-09-12 2006-02-14 Merck & Co., Inc. Antifungal combination therapy
US5936062A (en) 1997-06-12 1999-08-10 Merck & Co., Inc. Process for preparing certain aza cyclohexapeptides
CA2375779A1 (en) 1999-05-31 2000-12-07 Mitsubishi Chemical Corporation Lyophilized hgf preparation
BR0107764A (pt) 2000-01-20 2002-11-12 Basilea Pharmaceutica Ag Composições de peptìdeo cìclico nasalmente administráveis
US6803046B2 (en) 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0715113A2 (pt) * 2006-07-26 2013-06-04 Sandoz Ag Sandoz Sa Sandoz Ltd formulaÇço de caspofungina
TW200826957A (en) 2006-10-16 2008-07-01 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Purification processes for echinocandin-type compounds
EP2170362B1 (en) 2007-06-26 2015-11-04 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
WO2009006301A2 (en) 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
CA2722602A1 (en) 2008-05-15 2009-11-19 Baxter International Inc. Stable pharmaceutical formulations
US20090291996A1 (en) 2008-05-21 2009-11-26 Ferenc Korodi Caspofungin free of caspofungin Co
US20100256074A1 (en) 2008-06-25 2010-10-07 Chaim Eidelman Processes for preparing high purity aza cyclohexapeptides
US20090324635A1 (en) 2008-06-25 2009-12-31 Ferenc Korodi Caspofungin free of caspofungin impurity A
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
TW201024322A (en) 2008-12-31 2010-07-01 Chunghwa Chemical Synthesis & Biotech Co Ltd Preparation method for nitrogen containing heterocyclic hexapeptide with high conversion rate
US9394340B2 (en) 2009-03-24 2016-07-19 Cadila Healthcare Limited Purification process for lipopeptides
CN102947327B (zh) 2010-03-29 2017-06-13 中化帝斯曼制药有限公司荷兰公司 卡泊芬净中间体的纯化
HRP20161236T1 (hr) 2010-09-20 2016-11-18 Xellia Pharmaceuticals Aps Kompozicija kaspofugina
US9056897B2 (en) 2010-09-28 2015-06-16 DSM Sinochem Pharmaceuticals Method for isolating a cyclohexapeptide
CA2826086A1 (en) 2011-01-03 2012-07-12 Biocon Limited Process for preparation of caspofungin acetate and intermediates
CN102166186A (zh) 2011-04-18 2011-08-31 深圳市健元医药科技有限公司 一种更加稳定的氮杂环己肽类制剂
CN102746384B (zh) 2011-04-22 2016-01-20 上海天伟生物制药有限公司 一种高纯度的卡泊芬净或其盐及其制备方法和用途
MX2013012161A (es) 2011-04-28 2014-07-30 Unitris Biopharma Co Ltd Compuesto intermedio de la sintesis de caspofungina y metodo de preparacion de la misma.
US9636407B2 (en) * 2012-11-20 2017-05-02 Fresenius Kabi Usa, Llc Caspofungin acetate formulations
WO2014177483A1 (en) 2013-05-02 2014-11-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Method for isolating caspofungin
EP3044230B1 (en) 2013-09-11 2021-06-16 Centrient Pharmaceuticals Netherlands B.V. Caspofungin derivative

Also Published As

Publication number Publication date
HK1215668A1 (en) 2016-09-09
US20140142032A1 (en) 2014-05-22
EP2922530B1 (en) 2016-09-14
CY1120016T1 (el) 2018-12-12
US20190105392A1 (en) 2019-04-11
US9636407B2 (en) 2017-05-02
EP2922530A1 (en) 2015-09-30
SMT201600452B (it) 2017-01-10
CA2888625A1 (en) 2014-05-30
HRP20161703T1 (hr) 2017-03-10
DK2922530T3 (en) 2017-01-09
LT2922530T (lt) 2017-01-25
SI2922530T1 (sl) 2017-04-26
US20160310597A1 (en) 2016-10-27
US20170296667A1 (en) 2017-10-19
ES2607646T3 (es) 2017-04-03
HUE032392T2 (en) 2017-09-28
PT2922530T (pt) 2016-12-22
WO2014081443A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
PL3181128T3 (pl) Kompozycja farmaceutyczna nilotynibu
ZA201500212B (en) Progesterone formulations
EP2910147A4 (en) CHAIR
AU345839S (en) Chair
EP2857033A4 (en) PEPTIDE WITH SKIN PERMEATION
PL2887958T3 (pl) Formulacje liposomowe
IL236911A0 (en) Trans-clomiphene formulations and their uses
PL2830589T3 (pl) Preparat nikotynowy
AU346460S (en) High chair
PT2916871T (pt) Produto de co-micronização compreendendo acetato de ulipristal
EP2861218A4 (en) LIPOSOME FORMULATIONS
PT2922530T (pt) Formulações de acetato de caspofungina
GB201200555D0 (en) Peptide
IL235988B (en) Drug composition is based on genotype or phenotype
GB201110278D0 (en) Formulations
GB201221125D0 (en) Pharmaceutial formulations
EP2891663A4 (en) PSF1-DERIVED PEPTIDE
GB201219818D0 (en) Chair
GB201206178D0 (en) Formulations
GB201211403D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations
PH32012001012S1 (en) Chairs
PH32012001013S1 (en) Chairs
PH32012000983S1 (en) Chair
AU343976S (en) Chair